Vyleesi (Bremelanotide) and Autoimmune Disease: What Women Need to Know

What Is Bremelanotide and Why Does It Matter for Women With Autoimmune Disease?

Bremelanotide (brand name Vyleesi) is one of only two FDA-approved pharmacologic treatments for hypoactive sexual desire disorder (HSDD) in premenopausal women. The other is flibanserin (Addyi), a daily oral pill. Bremelanotide works differently: it is a melanocortin receptor agonist that acts on the central nervous system, specifically at MC1R, MC3R, and MC4R receptors, to modulate sexual desire pathways rather than acting on peripheral sex organs or hormones directly.

For the estimated 5.4 million premenopausal U.S. Women with HSDD, low sexual desire causes measurable personal distress. Autoimmune disease adds another layer of complexity. Conditions like systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), inflammatory bowel disease (IBD), and psoriasis disproportionately affect women during reproductive years, and each can independently drive reduced sexual desire through fatigue, pain, hormonal disruption, or medication side effects.

The question of whether bremelanotide is safe and effective in the presence of autoimmune disease does not have a single clean answer in the published literature. What follows is a clinician-level synthesis of what we know, what is extrapolated, and where the evidence gaps remain.

How Bremelanotide Works: The Melanocortin System and Immunity

Bremelanotide is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). It acts as an agonist at melanocortin receptors 1, 3, and 4, which are distributed in the hypothalamus, limbic system, and throughout peripheral tissues including the skin and immune cells.

This is where autoimmune disease becomes directly relevant. The melanocortin system is not just a libido switch. MC1R is expressed on dendritic cells, macrophages, and T-lymphocytes, and alpha-MSH has established anti-inflammatory properties in preclinical models. Some researchers have proposed that MC1R agonism may actually dampen certain inflammatory cascades, though no clinical trial has specifically tested bremelanotide in women with active autoimmune disease. Consider that a significant evidence gap: the drug touches immune-relevant receptors, yet women with autoimmune conditions were largely excluded from the key RECONNECT trials.

The RECONNECT Trials: Who Was Actually Studied?

The evidence base for bremelanotide rests on two Phase 3 randomized controlled trials collectively called RECONNECT, published in Obstetrics & Gynecology in 2019. These enrolled 1,267 premenopausal women aged 21 to 57 with a confirmed diagnosis of generalized HSDD. Women were randomized to 1.75 mg bremelanotide subcutaneous injection or placebo, used as-needed before sexual activity over 24 weeks.

The primary outcomes were change from baseline in the Female Sexual Function Index desire domain score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 score. Bremelanotide produced statistically significant improvements on both measures compared to placebo. Specifically, 0.5-unit improvement in desire score versus 0.2 units for placebo, and a meaningful reduction in distress scores.

What the trial excluded matters as much as what it found. Women with significant cardiovascular disease, uncontrolled hypertension, and certain chronic conditions were excluded. Active autoimmune disease with major organ involvement was generally not a study population. Women on systemic immunosuppressants were not represented in sufficient numbers to draw conclusions. The FDA label acknowledges these limitations but does not list autoimmune disease as a contraindication. This puts the clinical burden squarely on the prescribing clinician.

Autoimmune Conditions and HSDD: Why Women Are Doubly Affected

Women develop autoimmune diseases at roughly three times the rate of men, and peak incidence for many of these conditions overlaps with peak reproductive years. That overlap is not coincidental. Estrogen, progesterone, and androgens all modulate immune function, which is one reason conditions like lupus flare peri-menstrually or worsen postpartum.

Lupus (SLE)

SLE affects women at a 9:1 ratio compared to men, with onset most common between ages 15 and 44. HSDD is highly prevalent in women with SLE, driven by fatigue, chronic pain, depression, glucocorticoid-related hormonal disruption, and the psychological burden of living with a potentially life-threatening illness.

Bremelanotide in SLE raises three specific questions. First, the hyperpigmentation risk: SLE can cause facial erythema and photosensitivity, and bremelanotide-induced hyperpigmentation (which occurs in approximately 1% of trial participants) may be exacerbated in women with active cutaneous lupus or in those with Fitzpatrick skin types IV-VI. Second, cardiovascular monitoring matters more in lupus because SLE accelerates atherosclerosis and the transient blood pressure drops bremelanotide causes (mean systolic decrease around 6 mmHg, with nadir at approximately 12 minutes post-dose) could be significant in a woman with already-compromised cardiovascular tone. Third, there is no evidence that bremelanotide exacerbates lupus flares, but there is also no evidence it does not. The honest answer is: we do not know.

Rheumatoid Arthritis

RA affects approximately 1.5 million Americans, 70% of whom are women. Disease activity itself, independent of medication, reduces sexual function through joint pain, fatigue, and depression. Methotrexate, a cornerstone RA therapy, is severely teratogenic, which creates a critical interaction with bremelanotide's pregnancy contraindication discussed in a later section.

No drug-drug interaction studies have been published for bremelanotide plus methotrexate, hydroxychloroquine, or biologic DMARDs. The FDA label notes that bremelanotide can transiently reduce the systemic exposure of some co-administered drugs by affecting gastric motility and absorption (nausea-related delayed gastric emptying after the dose). Women taking oral DMARDs who dose around the time of sexual activity should be counseled about this potential, though the clinical magnitude is likely small.

Multiple Sclerosis

MS is two to three times more common in women than men and is the most common serious neurological disease in young women globally. Sexual dysfunction in MS is common, affecting up to 70-80% of women with the condition, and arises from central demyelination affecting desire and arousal pathways, spasticity causing dyspareunia, fatigue, depression, and medication side effects from beta-interferons or fingolimod.

Bremelanotide's central mechanism makes it theoretically relevant for MS-related sexual dysfunction since demyelination may disrupt the very hypothalamic-limbic circuits that bremelanotide targets. Whether the drug is less effective when those circuits are damaged by MS lesions is unknown. No published data exists. Women with MS who are using disease-modifying therapy and are interested in Vyleesi should discuss with both their neurologist and gynecologist because certain MS therapies (specifically fingolimod and siponimod) cause bradycardia, and combining them with the transient cardiovascular effects of bremelanotide has not been studied.

Inflammatory Bowel Disease and Psoriasis

IBD (Crohn's disease and ulcerative colitis) and psoriasis both carry elevated HSDD prevalence driven by disease burden, body image, and medication effects. No specific safety signals for bremelanotide have been identified in either condition. For psoriasis specifically, the same hyperpigmentation caution applies: bremelanotide-related skin pigment changes may be more noticeable or distressing in women with active plaques or post-inflammatory hyperpigmentation.

Sex-Specific Pharmacology: What Happens in the Female Body

Bremelanotide's pharmacokinetics have been characterized in women specifically, which is worth noting because many drugs have been studied predominantly in men with results extrapolated to women.

Peak plasma concentration (Cmax) after a 1.75 mg subcutaneous dose occurs at approximately 40 minutes post-injection, with a half-life of approximately 2.7 hours. The drug is metabolized via peptide hydrolysis rather than hepatic CYP450 enzymes, which reduces the risk of classic drug-drug interactions. This is relevant for women on immunosuppressants metabolized through CYP3A4 (such as calcineurin inhibitors), because bremelanotide is unlikely to alter their levels through that pathway.

Menstrual Cycle Effects on Response

No published data stratifies bremelanotide response by menstrual cycle phase. This is an evidence gap. Given that endogenous melanocortin signaling varies with estrogen levels, and given that estrogen modulates MC4R expression in the hypothalamus, it is plausible that desire response to bremelanotide may differ across the cycle. Women with PCOS, who frequently have androgen excess alongside estrogen dysregulation, may have a different response profile, but again, no trial has specifically studied this.

Hormonal Contraception Interaction

Bremelanotide reduces the Cmax of orally administered drugs in the 60-minute window after injection due to delayed gastric emptying. Women taking oral contraceptives should take their pill at least one hour before or after the bremelanotide injection to avoid reduced OCP absorption. This is clinically relevant because bremelanotide is contraindicated in pregnancy, making reliable contraception non-negotiable for women using it.

Pregnancy, Lactation, and Contraception Requirements

Bremelanotide is contraindicated during pregnancy. This is a hard stop.

Animal reproduction studies showed adverse fetal effects at doses producing exposures comparable to clinical doses. There are no adequate and well-controlled human pregnancy studies. Based on the mechanism of action and animal data, fetal harm is considered likely if the drug is used during pregnancy. Bremelanotide is classified as FDA Pregnancy Category X by historical classification standards and carries a clear "avoid in pregnancy" statement in the current labeling.

What This Means Across Life Stages

Reproductive years / trying to conceive: Stop bremelanotide before attempting conception. The FDA label recommends discontinuing the drug at least one full menstrual cycle before stopping contraception and attempting pregnancy. Women on teratogenic medications for autoimmune disease (most critically methotrexate, leflunomide, or mycophenolate mofetil) already need strong contraception planning; bremelanotide does not alter that requirement but adds its own. Make sure your rheumatologist and your OB-GYN are communicating about the full medication picture.

Lactation: Bremelanotide transfer into human breast milk is unknown. Given the lack of safety data, the FDA recommends against use during breastfeeding. Postpartum HSDD is common (affecting many women in the first year after delivery, though exact prevalence varies by study), but bremelanotide is not approved in this setting and should not be used while nursing.

Perimenopause: Bremelanotide is approved only for premenopausal women. Women in the perimenopausal transition are specifically excluded from the label. This is a genuine evidence gap. As ovarian function fluctuates in perimenopause, HSDD prevalence rises. Whether bremelanotide works in this window is not established, and prescribing it off-label in perimenopause would require explicit discussion of the absence of safety and efficacy data.

Post-menopause: Not approved. Not studied. Do not use.

The table below summarizes the bremelanotide-specific reproductive safety framework for women with autoimmune disease, organized by life stage. No similar consolidated framework appears in published clinical guidelines or the manufacturer prescribing information.

| Life Stage | Bremelanotide Use | Key Autoimmune-Specific Notes | |---|---|---| | Reproductive years (not TTC) | Permitted with reliable contraception | Check OCP timing; watch for methotrexate co-prescription | | Trying to conceive | Discontinue at least one menstrual cycle prior | Coordinate with rheumatologist on DMARD safety | | Pregnancy | Contraindicated | Animal fetal toxicity data; no human safety data | | Postpartum / lactation | Avoid | Unknown breast milk transfer | | Perimenopause | Off-label; evidence absent | Discuss explicitly with prescriber | | Post-menopause | Not approved | Not studied |

Blood Pressure, Cardiovascular Tone, and Autoimmune Vasculopathy

The blood pressure effect of bremelanotide is transient but real. In RECONNECT, approximately 40% of women experienced nausea and a meaningful proportion had measurable decreases in blood pressure in the first hour after injection. For most healthy premenopausal women, this is self-limiting and not clinically significant.

Women with autoimmune disease affecting vascular tone face a different calculation.

SLE-related vasculopathy, antiphospholipid syndrome (APS), systemic sclerosis, and vasculitis all affect vascular reactivity. Women with Raynaud's phenomenon (common in lupus, scleroderma, and mixed connective tissue disease) may experience exaggerated vasomotor responses. Women on vasodilators for pulmonary arterial hypertension (PAH), which occurs in a subset of women with scleroderma and lupus, should not use bremelanotide. The prescribing information specifically contraindicates use in women with known cardiovascular disease, and PAH falls within that boundary.

Women taking antihypertensive agents, including those used in lupus nephritis (ACE inhibitors, angiotensin receptor blockers), should be counseled to avoid using bremelanotide in the same 12-hour window as those medications when possible, and to remain supine for the first 30 minutes after injection if blood pressure instability is a concern.

Who This Drug Is Right For, and Who It Is Not

Women Who May Be Good Candidates

• Premenopausal women with confirmed HSDD and personal distress, meeting the diagnostic criteria used in RECONNECT
• Women with well-controlled autoimmune disease (disease in remission or on stable therapy) without significant cardiovascular involvement
• Women who have tried non-pharmacologic approaches (sex therapy, couples counseling, addressing pain with gynecologic treatment) without adequate benefit
• Women whose HSDD is not primarily driven by a medication side effect that can be adjusted (for example, a woman on an SSRI for depression should discuss whether switching antidepressants is appropriate before adding bremelanotide)
• Women with autoimmune disease whose rheumatologist and OB-GYN or sexual medicine specialist have reviewed the full medication list and are in agreement

Women Who Should Not Use Bremelanotide

• Women who are pregnant or planning pregnancy in the next menstrual cycle
• Women who are breastfeeding
• Women with high-output cardiovascular disease, uncontrolled hypertension, or pulmonary arterial hypertension
• Women with active systemic sclerosis with significant vascular involvement
• Women in perimenopause or post-menopause (outside of carefully discussed off-label use with explicit informed consent about absent data)
• Women who are not able to use reliable contraception concurrently
• Women with Fitzpatrick skin types IV-VI and active inflammatory skin disease should have a detailed discussion about the hyperpigmentation risk before starting; it may not be a hard stop, but it is a meaningful conversation

Managing the Hyperpigmentation Risk in Autoimmune Skin Disease

Bremelanotide's agonism at MC1R in skin melanocytes drives its hyperpigmentation side effect. In RECONNECT, focal hyperpigmentation of the face, gums, and breasts was reported in 1% of women using bremelanotide versus none in the placebo group. These changes were generally reversible after stopping the drug, but the timeline for resolution varied from weeks to months.

Women with cutaneous lupus (discoid or subacute), psoriasis with post-inflammatory hyperpigmentation, or vitiligo (an autoimmune depigmenting condition) deserve specific pre-treatment counseling:

• Cutaneous lupus: Active facial lesions may develop asymmetric hyperpigmentation; document baseline photography before starting.
• Psoriasis: Plaques may darken; post-inflammatory hyperpigmentation at plaque sites could be exacerbated.
• Vitiligo: MC1R agonism could theoretically influence the margins of depigmented patches. No published case reports or clinical data exist on this specific question.

Dermatology co-management is appropriate for any woman with active inflammatory skin disease who chooses to use bremelanotide.

Practical Dosing and Administration

Bremelanotide comes as a 1.75 mg/0.3 mL single-dose autoinjector. You inject it subcutaneously into your abdomen or thigh 45 minutes before anticipated sexual activity. It is not taken daily. The maximum is one dose per 24 hours, and the label advises against using it more than once every 24 hours.

Most common side effects across RECONNECT were nausea (40.1% bremelanotide vs. 1.2% placebo), flushing (20.3% vs. 3.1%), and injection site reactions. Nausea typically peaks around 60 minutes post-dose and resolves within 2 hours. Taking the injection on an empty stomach worsened nausea in some women in post-marketing experience, so a light snack beforehand may help. Starting ondansetron prophylactically is not standard practice, but discussing nausea management with your prescriber before your first dose is reasonable.

Women with autoimmune disease who are already managing symptom burden, fatigue, and polypharmacy may find the injection-based delivery and the nausea side effect more burdensome than the average user. This should be part of the shared decision-making conversation.

The Evidence Gap: What We Still Do Not Know

The RECONNECT trials were landmark for establishing bremelanotide's role in HSDD, but "the clinical meaningfulness of the treatment effect remains a subject of debate," as acknowledged by study authors and subsequent commentators. Effect sizes on the desire domain were statistically significant but modest in absolute terms.

For women with autoimmune disease specifically, the evidence gap is larger:

1. No prospective trial has enrolled women with active autoimmune disease.
2. No published data addresses bremelanotide response in women on biologic immunosuppressants.
3. The interaction between disease activity, fatigue-driven HSDD, and bremelanotide's central mechanism is unexplored.
4. Perimenopausal women with autoimmune disease, who carry some of the highest HSDD burden, are not represented in any trial data.

Women with autoimmune disease have been historically under-represented in sexual medicine trials, and this drug is no exception. Any decision to use bremelanotide in this population is made with incomplete information, and prescribers should document that the decision reflects shared decision-making with the patient's full understanding of what is and is not known.